Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Northeast Pharmaceutical Group Co (SZSE:000597) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Northeast Pharmaceutical Group Co EBITDA Margin % Related Terms
Northeast Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northeast Pharmaceutical Group Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Northeast Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northeast Pharmaceutical Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Northeast Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Northeast Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northeast Pharmaceutical Group Co (SZSE:000597) has a EBITDA Margin % of 6.05% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Northeast Pharmaceutical Group Co and its competitors. This is 41% below median its historical median of 10.28. Over the past decade, Northeast Pharmaceutical Group Co's EBITDA Margin % has ranged from 4.15 to 16.40. According to the industry distribution chart, Northeast Pharmaceutical Group Co ranks #649 out of 961 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Northeast Pharmaceutical Group Co's EBITDA Margin % too high?
Northeast Pharmaceutical Group Co's current EBITDA Margin % of 6.05% is 41% below median its 10-year median of 10.28. Over the past 10 years, this metric has ranged from a low of 4.15 to a high of 16.40. The Drug Manufacturers industry median EBITDA Margin % is 11.88. Northeast Pharmaceutical Group Co's value of 6.05% is 49.1% below this industry median. Based on the distribution chart, Northeast Pharmaceutical Group Co ranks #649 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Northeast Pharmaceutical Group Co has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Northeast Pharmaceutical Group Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Northeast Pharmaceutical Group Co ranks #649 out of 961 companies for EBITDA Margin %. This places Northeast Pharmaceutical Group Co in the lower half of its industry. The industry median EBITDA Margin % is 11.88. Northeast Pharmaceutical Group Co's value of 6.05% is 49.1% below this benchmark. Historically, Northeast Pharmaceutical Group Co's own EBITDA Margin % has ranged from 4.15 to 16.40 over the past decade. While the company's 10-year median is 10.28 vs. the industry median of 11.88, Northeast Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.88, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Northeast Pharmaceutical Group Co's current EBITDA Margin % of 6.05% is 49.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Northeast Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Northeast Pharmaceutical Group Co's current EBITDA Margin % is 6.05%, which is 41% below median its own 10-year median of 10.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northeast Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Northeast Pharmaceutical Group Co (SZSE:000597) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥4.21, compared to a current price of ¥4.74 — trading 12.6% above its estimated fair value. The current EBITDA Margin % is 6.05%, which is 41% below median its 10-year median of 10.28 and 49.1% below the Drug Manufacturers industry median of 11.88. Northeast Pharmaceutical Group Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Northeast Pharmaceutical Group Co (SZSE:000597), the current EBITDA Margin % is 6.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Northeast Pharmaceutical Group Co (SZSE:000597) Overvalued in 2026?
Based on GuruFocus' analysis, Northeast Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥4.74 is trading 12.6% above its estimated GF Value™ of ¥4.21.
GuruFocus considers Northeast Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SZSE:000597:
EBITDA Margin %: 6.05% (41% below median its 10-year median of 10.28)
GF Value™: ¥4.21 vs. price of ¥4.74 (12.6% above fair value)
Industry Position: 49.1% below the Drug Manufacturers median (#649 of 961)
No single metric tells the full story. See the SZSE:000597 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Northeast Pharmaceutical Group Co Ltd is engaged in the production and distribution of ammonium phosphate, sulfuric acid, cement, compound fertilizer, bromine, raw salt, and diammonium phosphate.
62GF Score
Get the complete analysis for SZSE:000597
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:000597 has been successfully added to your 
